Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents.
Cholangiocarcinomas are devastating cancers that are resistant to chemotherapies. Resveratrol, a food-derived polyphenol with antitumorigenic properties, can regulate the expression of cytochrome p450 1b1 (Cyp1b1), which may confer chemoresistance in various cancers. Our aims were to assess the effects of resveratrol on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents and show an association between Cyp1b1 expression and chemosensitivity. Cholangiocarcinoma cell lines were treated with resveratrol before the addition of 5-fluorouracil (5-FU), gemcitabine, or mitomycin C. Cell proliferation and apoptosis were assessed by MTS assays and Annexin staining. Resveratrol effects on cholangiocarcinoma tumor sensitivity to 5-FU was assessed in an in vivo xenograft model using Mz-ChA-1 cells. After resveratrol treatment, Cyp1b1 expression was assessed by real-time PCR and immunoblotting. Stable-transfected cell lines with Cyp1b1 expression knocked down (Mz-Cyp1b1) were used to assess sensitivity to chemotherapeutic agents by MTS assays and Annexin staining and in a xenograft model using Mz-ChA-1 and Mz-Cyp1b1 cells, respectively. For each chemotherapeutic agent, co-treatment with resveratrol in vitro decreased cell proliferation and increased apoptosis to a greater extent than with the chemotherapeutic agent alone. In vivo, 5-FU+resveratrol decreased tumor size and increased TUNEL staining to a greater extent than 5-FU alone. In parallel, resveratrol decreased Cyp1b1 expression in Mz-ChA-1 cells and in cholangiocarcinoma tumors. Mz-Cyp1b1 cells were more sensitive to chemotherapeutic agents in vitro than mock-transfected cells, and Mz-Cyp1b1-induced tumors were more susceptible to 5-FU treatment. We suggest that resveratrol treatment may be a useful adjunct therapy to improve chemosensitivity in cholangiocarcinoma.
Frampton
Gabriel A
GA
Department of Internal Medicine, Texas A&M Health Science Center, College of Medicine, Temple, TX, USA.
Lazcano
Eric A
EA
Li
Huang
H
Mohamad
Akimuddin
A
DeMorrow
Sharon
S
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D003577:Cytochrome P-450 Enzyme System / Q000494:pharmacology; D003841:Deoxycytidine / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D016685:Mitomycin / Q000494:pharmacology / Q000627:therapeutic use; D000077185:Resveratrol; D013267:Stilbenes; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D013267:Stilbenes; D003841:Deoxycytidine; D016685:Mitomycin; D003577:Cytochrome P-450 Enzyme System; D000077185:Resveratrol; D005472:Fluorouracil; D000093542:Gemcitabine
In Vitro Cell Dev Biol. 1989 Jun;25(6):503-10
2544546
Clin Liver Dis. 2008 Feb;12(1):131-50, ix
18242501
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):219-28
19362240
J Hepatol. 2007 Feb;46(2):222-9
17069924
Phytother Res. 2009 Feb;23(2):226-30
18726924
Hepatology. 2003 May;37(5):961-9
12717374
Pancreatology. 2008;8(6):566-76
18824880
J Androl. 2007 Mar-Apr;28(2):282-93
17050787
J Biol Chem. 2007 Apr 27;282(17):13098-113
17329257
J Biol Chem. 2007 Jul 6;282(27):19385-98
17513867
J Clin Gastroenterol. 2007 Nov-Dec;41(10):894-900
18090157
Mol Nutr Food Res. 2007 May;51(5):517-24
17440990
Cancer. 2009 Aug 15;115(16):3738-48
19514085
J Hepatol. 1985;1(6):579-96
4056357
Biomed Pharmacother. 2008 Nov;62(9):622-9
18804944
Drug Metab Dispos. 1997 May;25(5):617-22
9152602
Cancer Res. 2004 May 15;64(10):3517-24
15150106
Neurosci Lett. 2004 Jun 17;363(3):257-61
15182955
Int J Cancer. 2004 Mar 20;109(2):182-8
14750167
Oncogene. 2004 Dec 9;23(57):9247-58
15489888
Genes Chromosomes Cancer. 1990 Nov;2(4):300-10
2176543
Int J Cancer. 2009 Aug 1;125(3):565-76
19358267
Cancer Res. 2009 Sep 1;69(17):7038-45
19690133
Am J Physiol. 1994 Jun;266(6 Pt 1):G1060-70
8023938
Int J Mol Med. 2006 Jun;17(6):1069-75
16685418
J Hepatol. 2008 Aug;49(2):160-2
18538440
Infect Disord Drug Targets. 2009 Aug;9(4):400-14
19689382
Cancer Res. 1997 Jul 15;57(14):3026-31
9230218
Anticancer Res. 2009 Feb;29(2):509-15
19331196
Toxicol Lett. 2010 Feb 1;192(2):221-8
19879933
Liver Int. 2009 May;29(5):670-7
19226332
Mol Cancer Ther. 2006 Aug;5(8):2034-42
16928824
Cancer Res. 2005 Dec 15;65(24):11437-46
16357152
Oncogene. 2004 Nov 25;23(55):8979-86
15480430
Int J Cancer. 2010 May 1;126(9):2112-22
19795457
Br J Cancer. 2001 Jul 20;85(2):242-6
11461084
Carcinogenesis. 1999 Aug;20(8):1607-13
10426814
Drug Metab Dispos. 2002 Nov;30(11):1149-52
12386117
Int J Cancer. 2002 Apr 10;98(5):761-9
11920648
Biochem Pharmacol. 2001 Jul 15;62(2):207-12
11389879
Carcinogenesis. 2004 Oct;25(10):2005-13
15142886
Int J Cancer. 1992 Sep 9;52(2):252-60
1355757
Cancer Res. 2002 Sep 1;62(17):4945-54
12208745
Am J Physiol Gastrointest Liver Physiol. 2008 Dec;295(6):G1150-8
18832445
Methods. 2001 Dec;25(4):402-8
11846609
Prostaglandins Leukot Essent Fatty Acids. 2005 Mar;72(3):219-26
15664307
J Biol Chem. 2003 Oct 17;278(42):41482-90
12902349
Carcinogenesis. 2002 Sep;23(9):1531-6
12189197
Annu Rev Pharmacol Toxicol. 2001;41:297-316
11264459
J Pharmacol Exp Ther. 2001 Feb;296(2):537-41
11160641
J Natl Cancer Inst Monogr. 2000;(27):95-112
10963622
Hepatology. 2005 Jan;41(1):5-15
15690474
Liver Int. 2008 Dec;28(10):1426-36
18397227
Science. 1997 Jan 10;275(5297):218-20
8985016
J Med Food. 2007 Jun;10(2):218-24
17651055